ClinicalTrials.gg
RecruitingNCT05584670Updated Jun 23, 2026

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of SAR445877 and Cetuximab in Solid Tumor, sponsored by Sanofi. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
542
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors.

The study will include 2 parts:

A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable.

A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generation aCTLA4 (ADG126) or with bevacizumab. 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable.

Approximately 542 participants will be exposed to the study intervention:

  • approximately 123 participants in part 1,
  • up to 410 participants in expansion/dose optimization part (part 2)
  • and up to 9 participants in Japan cohort F.
Read the detailed description

The duration of the study for a participant will include:

  • Screening Period: up to 28 days
  • Treatment Period: enrolled and exposed participants will receive continuous treatment until progressive disease (PD), or an occurrence of an unacceptable AE, a withdrawal of consent, or until other permanent discontinuation criteria described in the protocol are met.

The End of Treatment (EOT) visit will occur 30 days ±7 days from the last IMP administration or prior to the initiation of further therapy, whichever occurs first.

The follow-up period will occur until disease progression, the start of new anticancer therapy, death, or withdrawal of participant's consent, whichever comes first.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Dose escalation Part 1A and Japan Cohort F

    • Participants with advanced unresectable or solid tumors for which, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant
  2. Dose escalation Part 1B

    • Participants with advanced unresectable or metastatic melanoma, NSCLC; renal cell carcinoma (RCC); HCC, colorectal cancer (MSI-H/dMMR), malignant pleural mesothelioma or esophageal squamous cell carcinoma (ESCC). and for who, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant.
  3. Dose escalation Part 1C

    • or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer
    • Participants with RAS-mutant and BRAF-mutant colorectal cancer are eligible for enrollment.
  4. Dose expansion/optimization Part 2

    Cancer diagnosis:

    • Participants in Cohorts A1 and A2 (Part 2A): Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)
    • Participants in Cohort B (part 2A): Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants (participants without cirrhosis must have had histological confirmation of diagnosis)
    • Participants in Cohorts C1 and C2 (part 2A):

      • Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer (GC) or Siewert Type 2 \& 3 gastro esophageal junction (GEJ) adenocarcinoma
      • Disease with any CPS scoring. No need for CPS determination at local laboratory
      • Participants must have MSI (metastatic microsatellite instability) or MMR (mismatch repair) status known or determined locally and must have non-MSI-H or proficient MMR (pMMR) disease to be eligible.
      • Participants with unknown /neu status must have their HER2/neu status determined locally. Participants with HER2/neu negative are eligible. Participants with HER2/neu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible.
    • Participants in Part 2A Cohorts E1 and E2, Part 2B Cohort E3 and Part 2D Cohorts H1 and H2: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer.
    • Participants in Part 2A Cohorts E1, and E2 and Part 2B Cohort E3 MSI status:

    Participants must have MSI status known or determined locally and must have non- MSI-H disease to be eligible.

    • Participants in Part 2A Cohorts E1, E2, Part 2B Cohort E3 and Part 2D Cohorts H1 and H2: Participants with RAS-mutant and BRAF-mutant colorectal cancer are eligible for enrollment.
    • Part 2C Cohorts G1, G2 and G3: Participants with histologically confirmed unresectable locally advanced or metastatic melanoma
  5. Prior anticancer therapy (For dose expansion/optimization Part 2 only)

    • Participants in Cohorts A1 and A2: Participants must have received at least 1 systemic therapy for the metastatic setting and must not be amenable to the available SOC.
    • Participants in Cohort B: Participants who have received at least 1 prior anticancer therapy, including an anti-PD1/ containing regimen, and for whom have progressed after a primary or secondary resistance to an anti-PD1/PD-L1.
    • Participants in Cohorts C1 and C2: Participants should have failed or after at least 1 which may or may not include an anti-PD1/PD-L1-based treatment depending on local standard of care.
    • Participants in Cohort D: Participants must have received at least 1 systemic therapy for their advanced/ metastatic setting and must not be amenable to the available SOC.
    • Participants in Part 2A Cohorts E1 and E2 and Part 2D Cohorts H1 and H2 should have failed or relapsed on at least 2 prior regimens.
    • Participants in cohort E3 should have failed or relapsed on at least 1 prior regimen. Participants who have received cetuximab or other anti-EGFR therapy as part of their prior line of treatment are eligible.
    • Part 2C Cohorts G1, G2 and G3: Participants must have received at least one prior line of therapy for advanced/metastatic melanoma and/or does not have any standard of care (SoC) treatment option or decline or is intolerant to be treated with SoC treatment.

:

  • At least 1 measurable lesion per 1.1 criteria

Part 1C and Part 2D: Adequate coagulation function for all participants. For participants receiving anti-coagulant therapy (except anti-aggregates) the adequate therapeutic levels of should be confirmed.

Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • (ECOG) performance status of ≥2
  • Predicted ≤3 months
  • For participants with HCC- Cohort B (Part 2): Class B or C liver score. Participants with Child Pugh Class B-7 score are allowed for Part 1.
  • Diagnosed of any other , either progressing or requiring active treatments, within 2 years prior to enrollment
  • Known active or
  • History of treatment-related immune-mediated (or immune-related) AEs from immune-modulatory agents (including but not limited to anti-PD1/ agents and anti-cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were Grade 4 in severity or have not resolved to Grade ≤1
  • Has any condition requiring ongoing/continuous therapy (>10 mg prednisone/day or an anti-inflammatory equivalent) within 1 week prior to the first dose of the study medicine
  • Any cardiac (including valvular) or vascular (thromboembolic disorders) disease, within 6 months prior to the first IMP administration
  • Ongoing or recent (within 2 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-related adverse events
  • Has a known history or any evidence of interstitial lung disease or active, non-infectious pneumonitis within 3 years prior to the first dose of the study drug.
  • Organ transplant requiring immunosuppressive treatment
  • Uncontrolled or active infection with (HIV), , or infection, or has a diagnosis of immunodeficiency

NOTE: Other Inclusion/Exclusion criteria may apply.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
542 participants (estimated)

Study arms

  • Experimental
    SAR445877 Escalation Phase (Part 1A)

    SAR445877 monotherapy will be administered intravenously in participants with solid tumors over a 14-day cycle.

    Drug: SAR445877

  • Experimental
    SAR445877 Escalation Phase (Part1B)

    SAR445877 will be administered intravenously in combination with ADG126 in participants with advanced unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC); renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), colorectal cancer (MSIH/dMMR), malignant pleural mesothelioma or esophageal squamous cell carcinoma (ESCC).

    Drug: SAR445877 · Drug: ADG126

  • Experimental
    SAR445877 Escalation Phase (Part 1C)

    SAR445877 will be administered intravenously in combination with bevacizumab in participants with metastatic colorectal cancer (CRC).

    Drug: SAR445877 · Drug: Bevacizumab

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A)

    SAR445877 monotherapy will be administered intravenously (IV) in participants with non-small cell lung cancer (NSCLC).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A)

    SAR445877 monotherapy will be administered intravenously (IV) in participants with non-small cell lung cancer (NSCLC).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A)

    SAR445877 monotherapy will be administered intravenously in participants with hepatocellular carcinoma (HCC).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A)

    SAR445877 monotherapy will be administered intravenously in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A)

    SAR445877 monotherapy will be administered intravenously in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A)

    SAR445877 monotherapy will be administered intravenously IV in participants with immune infiltrated tumor type.

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2B)

    SAR445877 monotherapy will be administered intravenously in participants with colorectal cancer (CRC).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/optimization Phase: Cohort E2 (Part 2A)

    SAR445877 monotherapy will be administered intravenously in participants with colorectal cancer (CRC).

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/optimization Phase: Cohort E3 (Part 2B)

    SAR445877 will be administered intravenously in combination with cetuximab in participants with colorectal cancer.

    Drug: SAR445877 · Drug: Cetuximab

  • Experimental
    SAR445877 Japan Cohort F

    SAR445877 monotherapy will be administered intravenously in participants with advanced unresectable or metastatic solid tumor, from Japan.

    Drug: SAR445877

  • Experimental
    SAR445877 Expansion/Optimization Phase Cohort G1 (Part 2C)

    SAR445877 will be administered intravenously in combination with ADG126 in participants with metastatic melanoma.

    Drug: SAR445877 · Drug: ADG126

  • Experimental
    SAR445877 Expansion/Optimization Phase Cohort G2 (Part 2C)

    SAR445877 will be administered intravenously in combination with ADG126 in participants with metastatic melanoma.

    Drug: SAR445877 · Drug: ADG126

  • Experimental
    SAR445877 Expansion/Optimization Phase Cohort G3 (Part 2C)

    The Standard of Care (nivolumab and ipilimumab) will be administered intravenously in participants with metastatic melanoma.

    Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    SAR445877 Expansion/Optimization Phase Cohort H1 (Part 2D)

    SAR445877 will be administered intravenously in combination with bevacizumab in participants with advanced unresectable or metastatic CRC.

    Drug: SAR445877 · Drug: Bevacizumab

  • Experimental
    SAR445877 Expansion/Optimization Phase Cohort H2 (Part 2D)

    SAR445877 will be administered intravenously in combination with bevacizumab in participants with advanced unresectable or metastatic CRC.

    Drug: SAR445877 · Drug: Bevacizumab

Interventions

  • Concentrate for solution for infusion

  • Solution for infusion

    Also known as: Erbitux

  • DrugADG126

    Solution for infusion

  • Solution for infusion

    Also known as: bevacizumab-bvzr, Zirabev®

  • Solution for infusion

    Also known as: Opdivo®

  • Solution for infusion

    Also known as: Yervoy®

06

What researchers measure

Primary outcomes

  1. Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2

    DLTs will be defined using NCI CTCAE version 5.0 or ASTCT criteria for CRS or immune effector cell-associated neurotoxicity syndrome (ICANS)

    Time frame: Cycles 1 & 2 - 14 days per cycle

  2. Dose escalation part 1B: Presence of dose-limiting toxicities (DLTs) in Cycle 1 to 3 in part B

    Time frame: Cycle 1 to 3 -14 days per cycle

  3. Dose escalation and Japan Cohort F: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Presence of TEAEs, SAEs, and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading

    Time frame: The time from the first dose of study interventions up to 30 days after last dose of study interventions

  4. Dose expansion/optimization: Objective response rate (ORR)

    Proportion of participants who have a confirmed complete response (CR) or a partial response (PR), as the best overall response (BOR) determined by the Investigator as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: From baseline to the end of dose expansion/optimization (up to 2 years)

Secondary outcomes

  1. Dose escalation and Japan Cohort F: Objective response rate (ORR)

    Proportion of participants who have a confirmed complete response (CR) or a partial response (PR), as the best overall response (BOR) determined by the Investigator as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: From baseline to the end of dose escalation (up to 2 years)

  2. Dose escalation, expansion/optimization and Japan Cohort F: Duration of response (DoR)

    DoR is defined as the time from first documented evidence of confirmed CR or PR until progressive disease (PD) determined by Investigator per RECIST 1.1 or death from any cause, whichever occurs first

    Time frame: From baseline to the end of study (up to 2 years)

  3. Dose escalation, expansion/optimization and Japan Cohort F: Assessment of SAR445877 Cmax

    Maximum plasma concentration observed

    Time frame: Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)

  4. Dose escalation, expansion/optimization and Japan Cohort F: Assessment of SAR445877 AUCtau

    Area under the concentration versus time curve calculated using the trapezoidal method during a dosing interval (T)

    Time frame: Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)

  5. Dose escalation, expansion/optimization and Japan Cohort F: Assessment of SAR445877 Tmax

    First time to reach Cmax

    Time frame: Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)

  6. Dose escalation, expansion/optimization in Combination: Assessment of combined therapies Ctrough

    Time frame: Day 1 of each cycle to cycle 4 (cycle duration of 14 days)

  7. Dose escalation, expansion/optimization and Japan Cohort F: Percentage of participants with presence of anti-drug antibodies (ADAs) against SAR445877

    Time frame: From the first dose of Cycle 1 to 30 days after last dose of study interventions (cycle duration of 14 days)

  8. Dose escalation, expansion/optimization: Percentage of participants with presence of anti-drug antibodies (ADAs) against ADG126

    Time frame: From the first dose of Cycle 1 to 30 days after last dose of study interventions (cycle duration of 14 days)

  9. Dose expansion/optimization: Time to response

    Time to response is defined as the time from the first administration of investigational medicinal product (IMP) to the first documented evidence of confirmed PR or CR determined by Investigator per RECIST 1.1

    Time frame: From baseline to end of dose expansion/optimization (up to 2 years)

  10. Dose expansion/optimization: Clinical Benefit Rate

    Clinical Benefit Rate including confirmed CR or PR at any time or stable disease (SD) of at least 6 months determined by Investigator per RECIST 1.1

    Time frame: From baseline to end of dose expansion/optimization (up to 2 years)

  11. Dose expansion/optimization: Progression-free survival

    PFS is defined as the time from the date of first administration of IMP to the date of the first documented disease progression determined by Investigator as per RECIST 1.1 or death from any cause, whichever occurs first

    Time frame: From baseline to end of dose expansion/optimization (up to 2 years)

  12. Dose expansion/optimization: Overall survival

    Overall survival (OS) is defined as the time from the first dose of IMP to the date of death due to any cause.

    Time frame: From baseline to end of dose expansion/optimization (up to 2 years)

  13. Dose expansion/optimization: Number of participants with Adverse events (AE)

    Presence of adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading

    Time frame: The time from the first dose of study interventions up to 30 days after last dose of study interventions.

07

Study locations

21 of 22 sites recruiting
  • Christiana Care Health System - Newark- Site Number : 8400011
    Newark, Delaware 19718, United States
    Recruiting
  • University of Iowa- Site Number : 8400014
    Iowa City, Iowa 52242, United States
    Recruiting
  • The University of Kansas Cancer Center - Westwood- Site Number : 8400008
    Westwood, Kansas 66205, United States
    Recruiting
    • Lisa Bogart · ContactCTNurseNav@kumc.edu · 913-945-7552
    • Joaquina Baranda · Principal investigator
  • Karmanos Cancer Institute - Detroit- Site Number : 8400006
    Detroit, Michigan 48201, United States
    Recruiting
    • Ammar Sukari · Contactsukaria@karmanos.org · 313-576-8751
    • Ammar Sukari · Principal investigator
  • John Theurer Cancer Center- Site Number : 8400001
    Hackensack, New Jersey 07601, United States
    Recruiting
  • NYU Langone Medical Center- Site Number : 8400013
    New York, New York 10016, United States
    Recruiting
  • Rhode Island Hospital - Providence - Eddy Street- Site Number : 8400004
    Providence, Rhode Island 02905, United States
    Recruiting
    • Kaitlyn Krar · ContactCKrar@Lifespan.org · 401-444-4818
    • Khaldoun Almhanna · Principal investigator
  • The University of Texas MD Anderson Cancer Center- Site Number : 8400005
    Houston, Texas 77030, United States
    Recruiting
  • Fred Hutchinson Cancer Center- Site Number : 8400010
    Seattle, Washington 98109, United States
    Recruiting
  • Servicios Médicos URUMED SpA_Investigational Site Number : 1520002
    Rancagua, General Bernardo O'Higgins 2852424, Chile
    Recruiting
  • BIOCINETIC Ltda_Investigational Site Number : 1520008
    Santiago, Reg Metropolitana de Santiago 8331143, Chile
    Recruiting
    • Nicolas Obando Martínez · Contactnicolas.obando@cecim.cl · 569 90790781
    • Nicolas Obando Martínez · Principal investigator
  • Centro de Investigacion Clinica Bradford Hill_Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
    Recruiting
    • Carlos Ignacio Rojas Garcia · Contactcirojas@bh.cl · 56 9 9874 4662
    • Carlos Ignacio Rojas Garcia · Principal investigator
  • Fundacion Arturo Lopez Perez (FALP) - Providencia - Jose Manuel Infante 805_Investigational Site Number : 1520007
    Providencia, 7500000, Chile
    Recruiting
    • Christian Caglevic Medina · Contactchristian.caglevic@falp.org · (562) 242-0509
    • Christian Caglevic Medina · Principal investigator
  • Hadassah Medical Center - PPDS_Investigational Site Number : 3760005
    Jerusalem, Jerusalem 9112001, Israel
    Recruiting
  • Sheba Medical Center - PPDS_Investigational Site Number : 3760003
    Ramat Gan, 5262100, Israel
    Recruiting
  • Tel Aviv Sourasky Medical Center Ichilov - PPDS_Investigational Site Number : 3760001
    Tel Aviv, 6423906, Israel
    Recruiting
    • Ravit Geva · Contactravitg@tlvmc.gov.il · 97236973494
    • Ravit Geva · Principal investigator
  • Shamir Medical Center_Investigational Site Number : 3760004
    Tzrifin, 7033001, Israel
    Recruiting
  • Investigational Site Number : 3920001
    Kashiwa, Chiba 277-8577, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis_Investigational Site Number : 5280001
    Amsterdam, North Holland 1066 CX, Netherlands
    Recruiting
    • Marloes van Dongen · Contactmg.v.dongen@nki.nl · 31205129111
    • Marloes van Dongen · Principal investigator
  • Erasmus MC_Investigational Site Number : 5280003
    Rotterdam, South Holland 3015 CE, Netherlands
    Recruiting
  • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON_Investigational Site Number : 7240007
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Elena Garralda · Contactegarralda@vhio.net · 34932746085
    • Elena Garralda · Principal investigator
  • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC_Investigational Site Number : 7240005
    Madrid, 28050, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Jan 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 18, 2022
StartActual
Nov 29, 2022
Primary completionEst.
Jan 19, 2027
CompletionEst.
Jun 28, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584670
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Nov 29, 2022
Primary completion
Jan 19, 2027 (estimated)
Completion
Jun 28, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6
Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daxokafusp Alfa

Start the discussion